Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)

Organon

Status and phase: Completed; Phase 4

Conditions: Pain

Treatments: Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days

Study type: Interventional

Funder types: Industry

Identifiers

NCT00380627

2006_035

0663-094

Details and patient eligibility

About

Allow gynecologists to gain experience with arcoxia for treatment of dysmenorrhea.

Sex: Female

Ages: 18 to 25 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Healthy women older than 18 years old and younger than 25 years old
• Voluntary agreement to participate in the study and signature of informed consent
• Women with clinical diagnosis of dysmenorrhea

Exclusion criteria

• Diagnosis of secondary dysmenorrhea due to: endometriosis, adenomyosis, malformations of Muller's conducts, uterine fibromyomas, ovarian cystic, pelvic varicocoele, inflammatory pelvic disease, adherences, intrauterine devices, cervical channel stenosis, etc.
• Patients with diagnosis of acute inflammatory abdomen
• Patients with diagnosis of congestive heart disease, stroke (1 year), unstable angina, and history of myocardial infarction
• Women auto prescribing rescue medication for dysmenorrheal pain during the study
• Women with a diagnosis of mild dysmenorrhea

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)